You are here
BLOOMBERG Commentary by Charles Kenney Feb. 3, 2015
...Without good surveillance, disease threats can fester undetected until they are considerably harder to contain. At the moment, countries simply declare they have the capacity to meet global standards and the WHO takes their word for it. There should be a system of independent review, backed up with international assistance and support to ensure that all countries really do have the capacity to track infectious disease outbreaks and control their spread across borders.
....the global health research system is primarily driven by market pressures. The cost of bringing a drug through the regulatory processes to market averages around $1 billion. That's a big reason why pharmaceutical companies would rather spend money on treatments for the diseases of the rich than for conditions that largely affect people in countries like Liberia...
There are two approaches to deal with that problem: lower the cost of drug development and increase the market for the products that emerge. ...
To increase demand, governments can club together to create an "advanced market commitment": If a drug developer produces a vaccine or therapy that meets certain standards, donors precommit to buy it in bulk....
Read complete article:
http://finance.yahoo.com/news/video-lessons-africas-hard-won-150502826.html;_ylt=AwrBEiEfDNFUnCUA0zHQtDMD
Recent Comments